Welcome to CDC stacks | Trends in Birth Weight and Gestational Age for Infants Born to HIV-infected, Antiretroviral Treatment-Naïve Women in Malawi - 33345 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Trends in Birth Weight and Gestational Age for Infants Born to HIV-infected, Antiretroviral Treatment-Naïve Women in Malawi
Filetype[PDF-362.13 KB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:

    We analyzed birth outcomes among infants of treatment-naïve, HIV-infected women from a series of mother-to-child transmission of HIV studies in Blantyre, Malawi.


    Data from six prospective studies at one research site were analyzed. Mean birth weight (BW) and gestational age (GA), and frequency of low birth weight (LBW; <2500 g) and preterm (PT) birth (GA<37 weeks) were estimated. We assessed risk factors for LBW and PT birth using mixed-effects logistic regression. Adjusted odds ratios (AOR) and 95% confidence intervals (CI) from earlier studies (1989-94) and later studies (2000-07) are presented separately.


    The analysis included 8874 HIV-exposed infants. Mean BW and GA ranged from 2793 to 3079 g, and 37.8 to 39.0 weeks. Greater maternal age was consistently (during both the early and late periods) associated with lower odds of LBW and PT birth; AOR (95% CI) for both outcomes in the early and late periods, respectively, were 0.98 (0.96-1.00) and 0.97 (0.95-0.99). Female infant gender was consistently associated with higher odds of PT birth during both periods and with higher odds of LBW during the later period. During the early period, higher maternal education was associated with lower odds of LBW (AOR 0.67 (0.48-0.95)) and PT birth (AOR 0.70 (0.51-0.95)) and later birth year was associated with lower odds of PT birth (AOR 0.35 (0.19-0.70)).


    BW and GA remained stable within each time period. This analysis provides important baseline information for monitoring HIV treatment effects on birth outcomes. Modifiable factors affecting BW and GA should continue to be explored.

  • Document Type:
  • Collection(s):
  • Funding:
    #5R03TW01199/TW/FIC NIH HHS/United States
    5-U50-PS022061-05/PS/NCHHSTP CDC HHS/United States
    N01-AI-35173-117/AI/NIAID NIH HHS/United States
    N01-CP-33005/CP/NCI NIH HHS/United States
    P01-AI-26499/AI/NIAID NIH HHS/United States
    R03 TW001199/TW/FIC NIH HHS/United States
    R03 TW001199-01/TW/FIC NIH HHS/United States
    R03 TW001199-01S1/TW/FIC NIH HHS/United States
    R03 TW001199-02/TW/FIC NIH HHS/United States
    R03 TW001199-03/TW/FIC NIH HHS/United States
    R03 TW001199-04/TW/FIC NIH HHS/United States
    R03 TW001199-05/TW/FIC NIH HHS/United States
    R03 TW001199-06/TW/FIC NIH HHS/United States
    R21-AI-33874-01/AI/NIAID NIH HHS/United States
    R24 HD042854/HD/NICHD NIH HHS/United States
    U01 AI048005/AI/NIAID NIH HHS/United States
    U01 AI048005-01/AI/NIAID NIH HHS/United States
    U01 AI048005-02/AI/NIAID NIH HHS/United States
    U01 AI048005-03/AI/NIAID NIH HHS/United States
    U01 AI048005-04/AI/NIAID NIH HHS/United States
    U01 AI048005-05/AI/NIAID NIH HHS/United States
    U01 AI048005-05S1/AI/NIAID NIH HHS/United States
    U01 AI048005-05S2/AI/NIAID NIH HHS/United States
    U01 AI048005-05S3/AI/NIAID NIH HHS/United States
    U01 AI048005-05S4/AI/NIAID NIH HHS/United States
    U01-AI-48005/AI/NIAID NIH HHS/United States
    U50-CC0222061/CC/ODCDC CDC HHS/United States
No Related Documents.
You May Also Like: